"Liver cancer, cirrhosis and nonalcoholic fatty liver disease are observed predominately in men. Being male or female is believed to be an important human variable that affects health and liver disease throughout the life span. However, few works have been"
Liver cancer, cirrhosis and nonalcoholic fatty liver disease are observed predominately in men. Being male or female is believed to be an important human variable that affects health and liver disease throughout the life span. However, few works have been published on the biological mechanisms underlying gender specific differences in liver disease. Several mechanisms underlying sex-associated differences of progression of liver disease are demonstrated in this book based on biological factors as estrogen and hepatic iron stores. Readers will gain a better understanding of the pathogenesis of these sex-associated differences in liver disease and on how to design healthcare for liver disease more effectively for individuals belonging to both genders. The book should be a useful reference on gender specific medicine for counselors and clinicians as well as for patients with chronic liver disease.
Chronic liver failure is a frequent condition in clinical practice that encompasses all manifestations of patients with end-stage liver diseases. Chronic liver failure is a multiorgan syndrome that affects the liver, kidneys, brain, heart, lungs, adrenal glands, and vascular, coagulation, and immune systems. Chronic Liver Failure: Mechanisms and Management covers for the first time all aspects of chronic liver failure in a single book, from pathogenesis to current management. Each chapter is written by a worldwide known expert in their area and all provide the latest state-of-the-art knowledge. This volume is specifically designed to provide answers to clinical questions to all doctors dealing with patients with liver diseases, not only clinical gastroenterologists and hepatologists, but also to internists, nephrologists, intensive care physicians, and transplant surgeons.
This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
This book focuses on patients with end-stage-liver disease (ESLD) who could possibly qualify for liver transplant. This patient cohort raises many problems: who should be treated and also, when is it too late for transplant? The authors are all dedicated experts in the field of ESLD/liver transplantation, but from different disciplines with different views of the problem. In the past 15 years many things have changed in the treatment for these patients: cardiac assessment, treatment of porto-pulmonary hypertension, hemodynamics, coagulation assessment and management, diagnosis of kidney failure, and the timing of dialysis. These issues are comprehensively discussed in this book, in order to provide physicians starting in the field of transplantation an overview of different areas of concern. This book is aimed at specialists and trainees in critical care, hepatology, anesthesia, surgery, and nephrology.
The second edition, which appears seven years after the first, is a more comprehensive text and addresses the many recent advances in basic and clinical science applicable to autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune aspects of viral-, drug- and alcohol-induced liver disease and hepatocellular cancer. Pathogenesis, diagnosis and treatment are discussed in depth in light of current understanding of the molecular mechanisms of autoimmunity as it applies to liver disease.
It's obvious why only men develop prostate cancer and why only women get ovarian cancer. But it is not obvious why women are more likely to recover language ability after a stroke than men or why women are more apt to develop autoimmune diseases such as lupus. Sex differences in health throughout the lifespan have been documented. Exploring the Biological Contributions to Human Health begins to snap the pieces of the puzzle into place so that this knowledge can be used to improve health for both sexes. From behavior and cognition to metabolism and response to chemicals and infectious organisms, this book explores the health impact of sex (being male or female, according to reproductive organs and chromosomes) and gender (one's sense of self as male or female in society). Exploring the Biological Contributions to Human Health discusses basic biochemical differences in the cells of males and females and health variability between the sexes from conception throughout life. The book identifies key research needs and opportunities and addresses barriers to research. Exploring the Biological Contributions to Human Health will be important to health policy makers, basic, applied, and clinical researchers, educators, providers, and journalists-while being very accessible to interested lay readers.
Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series
The oral board exam for the American Board of Oral and Maxillofacial Surgery (ABOMS) can be intimidating to many surgeons due to the broad range of information one must know for the exam. However, while the examination guidelines provide a general outline of topics that may be covered, there is no true direction on how to prepare for it. Traditionally, candidates do so by using what are considered “underground” databanks, previous test questions, and power point presentations that run the gamut of commonly covered material. Until now, there have been no current comprehensive oral board review books available for the Oral and Maxillofacial Surgery boards. Oral Board Review for Oral and Maxillofacial Surgery fills that gap as the go-to resource for those attempting to successfully challenge the oral boards and for residents to polish up on their training. Edited and authored by top physicians in the field, this book is concise and easy to read, yet thorough with high yield information. An outline of the pertinent material is reviewed, and a patient work up is presented. Important questions to ask, signs to look for, and labs/images to order are included. It also includes tables and keywords that are typically mentioned on the exam and also offers explanations to some key points. Next are cases, which are presented in a question and answer format. As the case progresses, more complicated scenarios requiring management are presented. Lastly, complications are covered, which is the final section of each board scenario. Included are basic topics the surgeon needs to know, followed by topics that are nice to know, and numerous highly debated/complex questions that are discussed among candidates preparing for the exam. It should be noted that the authors are not privy to any inside information about the exam. What is presented is material candidates that have successfully passed the exam feel is important to know. This book is not endorsed by American Association of Oral and Maxillofacial Surgeons or the American Board of Oral and Maxillofacial Surgery.